New Study Finds Current Heart Attack Screening Tools Miss 45 Percent of People at Risk

Day 1 conference highlights include news from Moderna, BridgeBio

DRRA23 hours ago 0

FDA again rejects tabelecleucel for EBV-driven post-transplant lymphoproliferative disease

DRRA23 hours ago 0

New data, nuances in managing resistant gram-negative infections

DRRA24 hours ago 0

New Year’s resolutions 2026: Lessons from colleagues

DRRA1 day ago 0